Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testing

Mayo Clinic Proceedings

Volumn 80, Issue 8, 2005, Pages 1063-1068

  Bundrick, John B ^a   Cook, David A ^a   Gostout, Bobbie S ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SCREENING; CYTOLOGY; DIAGNOSTIC TEST; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; LIQUID BASED CYTOLOGY; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; PAPANICOLAOU TEST; PRACTICE GUIDELINE; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

EID: 23244437744     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.8.1063     Document Type: Review

References (12)

1. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
2. U.S. Preventive Services Task Force (USPSTF). Recommendations and rationale: screening for cervical cancer. Available at: www.ahrq.gov/clinic/ 3rduspstf/cervcan/cervcanrr.htm. Accessibility verified June 15, 2005.
3. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2003;102:417-427.
4. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ, ASCCP-Sponsored Consensus Conference. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287: 2120-2129.
5. Pearce KF, Haefner HK, Sarwar SF, Nolan TE. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med. 1996;335:1559-1562.
6. Lee KR, Ashfaq R, Birdsong GG, Corkill ME, McIntosh KM, Inborn SL. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol. 1997;90:278-284.
7. Klinkhamer PJ, Meerding WJ, Rosier PF, Hanselaar AG. Liquid-based cervical cytology. Cancer. 2003;99:263-271.
8. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
9. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
10. Davey DD, Austin RM, Birdsong G, et al. ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators. J Lower Genital Tract Dis. 2002;6:195-199.
11. Solomon D, Schiffman M, Tarone R, ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
12. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382-2390.